(Q43138240)

14 November 2017

Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers (English)

1 reference

triacylglycerol lipase inhibitor

14 November 2017

1 reference

Andrew Bryson

1

1 reference

14 November 2017

Stephan de la Motte

series ordinal

2

1 reference

14 November 2017

Christopher Dunk

series ordinal

3

1 reference

14 November 2017

language of work or name

English

0 references

publication date

19 September 2008

1 reference

British Journal of Clinical Pharmacology

14 November 2017

1 reference

14 November 2017

67

1 reference

14 November 2017

3

1 reference

14 November 2017

309-315

1 reference

Orlistat-associated adverse effects and drug interactions: a critical review

14 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2675041

Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2675041

Clinical evaluation of anti-obesity drugs

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2675041

Anti-obesity drug development

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2675041

Benefits of sustained moderate weight loss in obesity.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2675041

Overweight, obesity, and health risk

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2675041

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2675041

Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2675041

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2675041

Trends in obesity and energy supply in the WHO MONICA Project

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2675041

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 December 2018

1 reference

12 December 2020

The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study

1 reference

12 December 2020

Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study

1 reference

12 December 2020

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

1 reference

12 December 2020

10.1111/J.1365-2125.2008.03311.X

Identifiers

DOI

1 reference

14 November 2017

1 reference

14 November 2017

PubMed publication ID

19220279

1 reference